Firibastat : a Novel Treatment for Hypertension
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
PURPOSE OF REVIEW: The purpose of this review is to discuss the unique mechanism of firibastat, a new antihypertension medication. Hypertension continues to be a highly prevalent public health issue.
RECENT FINDINGS: Firibastat is a novel agent developed to treat hypertension. As the first member in the class of centrally acting agents to target the brain renin angiotensin system, firibastat offers new pathways to consider and enhances the regimen of agents currently available to treat hypertension. Recent clinical trials have demonstrated effectiveness and safety in mild hypertension as well as resistant hypertension. This review introduces firibastat as a new therapeutic class of treatment for hypertension focused on the renin angiotensin system in the brain. Early studies have shown a significant reduction in blood pressure with minimal side effects particularly in patients who are difficult to treat.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Current hypertension reports - 23(2021), 12 vom: 24. Dez., Seite 46 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nesbitt, Shawna D [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 25.01.2022 Date Revised 25.01.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11906-021-01163-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM33486867X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33486867X | ||
| 003 | DE-627 | ||
| 005 | 20231225224625.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11906-021-01163-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1116.xml |
| 035 | |a (DE-627)NLM33486867X | ||
| 035 | |a (NLM)34950965 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nesbitt, Shawna D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Firibastat |b a Novel Treatment for Hypertension |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.01.2022 | ||
| 500 | |a Date Revised 25.01.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a PURPOSE OF REVIEW: The purpose of this review is to discuss the unique mechanism of firibastat, a new antihypertension medication. Hypertension continues to be a highly prevalent public health issue | ||
| 520 | |a RECENT FINDINGS: Firibastat is a novel agent developed to treat hypertension. As the first member in the class of centrally acting agents to target the brain renin angiotensin system, firibastat offers new pathways to consider and enhances the regimen of agents currently available to treat hypertension. Recent clinical trials have demonstrated effectiveness and safety in mild hypertension as well as resistant hypertension. This review introduces firibastat as a new therapeutic class of treatment for hypertension focused on the renin angiotensin system in the brain. Early studies have shown a significant reduction in blood pressure with minimal side effects particularly in patients who are difficult to treat | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Aminopeptidase A | |
| 650 | 4 | |a Angiotensin III | |
| 650 | 4 | |a Blood pressure | |
| 650 | 4 | |a Brain renin angiotensin system | |
| 650 | 4 | |a Firibastat | |
| 650 | 4 | |a Hypertension | |
| 650 | 7 | |a Antihypertensive Agents |2 NLM | |
| 650 | 7 | |a Disulfides |2 NLM | |
| 650 | 7 | |a Sulfonic Acids |2 NLM | |
| 650 | 7 | |a firibastat |2 NLM | |
| 650 | 7 | |a 638KY4573I |2 NLM | |
| 650 | 7 | |a Glutamyl Aminopeptidase |2 NLM | |
| 650 | 7 | |a EC 3.4.11.7 |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Current hypertension reports |d 1999 |g 23(2021), 12 vom: 24. Dez., Seite 46 |w (DE-627)NLM109021290 |x 1534-3111 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2021 |g number:12 |g day:24 |g month:12 |g pages:46 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11906-021-01163-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2021 |e 12 |b 24 |c 12 |h 46 | ||